Mylan reiterates profit on EpiPen two-pack in U.S.

(Reuters) - Under fire generic drugmaker Mylan NV reiterated it makes a net profit of $104, after taxes, for a pair of its EpiPen emergency allergy treatment sold in the United States, the company said in a filing on Monday.